M. Blasco

发表

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2017 .

Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2019, Clínica e Investigación en Arteriosclerosis (English Edition).

Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis Society

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2020 .

Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2017, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Consensus document on the management of the atherogenic dyslipidaemia of the Spanish Society of Arteriosclerosis.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2017 .

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment (II). The treatment of nonalcoholic fatty liver disease.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2017, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration

A. Hernández-Mijares, Á. Brea, X. Pintó, 2018, Clínica e Investigación en Arteriosclerosis (English Edition).

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease.

J. Pedro-Botet, Á. Brea, X. Pintó, 2017, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Clinical characteristics and outcomes of hospitalized patients with SARS-CoV-2 infection in a Latin American country: Results from the ECCOVID multicenter prospective study

O. Sued, Marisa Sánchez, M. Stryjewski, 2021, PloS one.

Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias

A. Hernández-Mijares, Á. Brea, X. Pintó, 2020, Clínica e Investigación en Arteriosclerosis (English Edition).

Utilization of evidence-based cardiovascular therapies and achievement of therapeutic goals in patients with peripheral artery disease.

J. Mostaza, C. Lahoz, M. Blasco, 2012, Revista espanola de cardiologia.

Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.

A. Hernández-Mijares, Á. Brea, X. Pintó, 2018, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (i). Nonalcoholic fatty liver disease and its association with cardiovascular disease

Á. Brea, X. Pintó, P. González-Sántos, 2017 .

Atherogenic Dyslipidaemia 2019. Consensus document of the Atherogenic Dyslipidaemia Group of the Spanish Arteriosclerosis Society.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2020, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Fibrates in the secondary prevention of cardiovascular disease (infarction and stroke). Results of a systematic review and meta-analysis of the Cochrane collaboration

A. Hernández-Mijares, Á. Brea, X. Pintó, 2018 .

Control of the overall lipid profile.

J. Ascaso, M. Blasco, 2019, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Control del perfil lipídico global

M. Blasco, J. Ascaso, 2019 .

Non-HDL cholesterol as a therapeutic goal.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2019, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Nonalcoholic fatty liver disease, association with cardiovascular disease and treatment. (I). Nonalcoholic fatty liver disease and its association with cardiovascular disease.

J. Pedro-Botet, Á. Brea, Á. Brea, 2017, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Residual cardiovascular risk of lipid origin. Components and pathophysiological aspects.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2019, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Triglycerides, HDL cholesterol and atherogenic dyslipidaemia in the 2019 European guidelines for the management of dyslipidaemias.

A. Hernández-Mijares, Á. Brea, X. Pintó, 2020, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Decalogue of the Spanish Society of Arteriosclerosis to reduce therapeutic inertia.

P. Pérez-Martínez, C. Lahoz, M. Blasco, 2017, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.

Fibrates in primary prevention of cardiovascular disease. Comments on the results of a systematic review of the Cochrane Collaboration.

J. Pedro-Botet, A. Hernández-Mijares, Á. Brea, 2018, Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis.